<p>广药集团（香港证券交易所代码：512）刚刚发布了 2025 财年的全年业绩，报告显示销售额增长，净收入大幅下降，年度股息减少，以及眼科药物 GPN01768 获得新的 NMPA 批准。</p>
<p>查看我们对广药集团的最新分析。</p>
<p>股价为 6.78 港元，单日股价回报率为 3.04%。30 天股价回报率为 12.52%，年初至今股价回报率为 13.08%，尽管三年总股东回报率为 70.98%，但短期动能正在减弱。</p>
<p>如果广药集团的最新业绩让你重新思考未来的增长来源，值得通过 124 只医疗保健人工智能股票扫描其他医疗保健公司。</p>
<p>由于股价远低于一些估值预期，尽管利润承压且股息被削减，投资者面临一个关键问题：在这次重置后，广药集团是否被低估，还是市场已经在定价其未来的增长？</p>
<h2>偏好的市盈率为 19.1 倍：这合理吗？</h2>
<p>在 19.1 倍的市盈率下，广药集团相对于其自身估计的合理市盈率显得略微便宜，但在当前 6.78 港元的股价下，相较于许多香港制药同行则显得更贵。</p>
<p>市盈率将当前股价与每股收益进行比较，是快速了解投资者为每单位利润支付多少的方式。对于像广药集团这样多元化的制药和医疗设备集团来说，这一点很重要，因为盈利质量、增长预测和行业风险都可能影响该倍数的高低。</p>
<p>根据 SWS 的合理比率研究，接近 22.5 倍的市盈率是合理的。这高于当前的 19.1 倍，并表明如果盈利预测和现金流符合预期，倍数可能有向该水平移动的空间。同时，股票的交易价格高于香港制药行业平均市盈率 12 倍。这表明市场已经根据其盈利状况和前景给予广药集团溢价。</p>
<p>探索广药集团的 SWS 合理比率</p>
<p><strong>结果：市盈率为 19.1 倍（被低估）</strong></p>
<p>然而，存在明显的风险，包括近期股价疲软、三年回报率为 70.98% 以及利润承压和股息减少。</p>
<p>了解广药集团叙述中的关键风险。</p>
<h2>另一种观点：DCF 信号显示更大的差距</h2>
<p>虽然 19.1 倍的市盈率表明广药集团看起来略微便宜，但 SWS DCF 模型指向截然不同的图景，估计每股价值为 22.44 港元，而当前股价为 6.78 港元，暗示股票被严重低估。在这种情况下，你更信任哪个信号？</p>
<p>了解 SWS DCF 模型如何得出其合理价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTI5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTI5"/></p>
<p>截至 2026 年 3 月的 512 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看广药集团）。我们展示完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 237 只高质量的被低估股票。如果你保存一个筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
<h2>下一步</h2>
<p>关于价值、增长和收入的混合信号可能会让人感到矛盾，因此快速查看完整的数字并形成自己的观点是有意义的。要权衡可能的利弊，请查看 3 个关键回报和 1 个重要警告信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果广药集团让你思考更深，不要止步于此。在数据仍然新鲜的情况下，将同样的纪律应用于其他机会。</p>
<ul>
<li>通过扫描 237 只高质量的被低估股票，发现潜在的错误定价，这些股票具有稳健的基本面和市场追赶的空间。</li>
<li>通过审查 471 只专注于更高收益且财务状况更健康的股息堡垒，增强你的收入流。</li>
<li>通过筛选 270 只低风险评分且在韧性和财务稳定性方面表现良好的股票，降低投资组合风险。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
<p>• 跟踪你股票的合理价值</p>
<p>免费试用演示投资组合</p>

远大医药

富国恒生港股通创新药及医疗保健ETF

创新药

<p>远大医药集团（SEHK:512）公布了 2025 年的业绩，销售额有所增加，但净收入下降，股息减少。当前股价为 6.78 港元，反映出每日回报率为 3.04%，30 天回报率为 12.52%。市盈率为 19.1 倍，表明与其根据现金流折现分析得出的每股公允价值 22.44 港元相比，可能被低估。然而，风险包括近期股价疲软和利润压力。投资者被鼓励评估关于增长和收入潜力的混合信号</p>

<p>Grand Pharmaceutical Group (SEHK:512) has just posted its full year 2025 results, reporting higher sales, sharply lower net income, a reduced annual dividend, and fresh NMPA approval for ophthalmic drug GPN01768.</p>
<div class="lb-trans"><p>广药集团（香港证券交易所代码：512）刚刚发布了 2025 财年的全年业绩，报告显示销售额增长，净收入大幅下降，年度股息减少，以及眼科药物 GPN01768 获得新的 NMPA 批准。</p>
</div><p>See our latest analysis for Grand Pharmaceutical Group.</p>
<div class="lb-trans"><p>查看我们对广药集团的最新分析。</p>
</div><p>The share price is HK$6.78 after a 3.04% 1 day share price return. The 30 day share price return of 12.52% and year to date share price return of 13.08% point to fading short term momentum despite a 3 year total shareholder return of 70.98%.</p>
<div class="lb-trans"><p>股价为 6.78 港元，单日股价回报率为 3.04%。30 天股价回报率为 12.52%，年初至今股价回报率为 13.08%，尽管三年总股东回报率为 70.98%，但短期动能正在减弱。</p>
</div><p>If Grand Pharmaceutical’s latest results have you rethinking where growth could come from next, it may be worth scanning other healthcare names through 124 healthcare AI stocks</p>
<div class="lb-trans"><p>如果广药集团的最新业绩让你重新思考未来的增长来源，值得通过 124 只医疗保健人工智能股票扫描其他医疗保健公司。</p>
</div><p>With the share price well below some valuation estimates, yet profits under pressure and the dividend trimmed, investors face a key question: is Grand Pharmaceutical undervalued after this reset, or is the market already pricing in its future growth?</p>
<div class="lb-trans"><p>由于股价远低于一些估值预期，尽管利润承压且股息被削减，投资者面临一个关键问题：在这次重置后，广药集团是否被低估，还是市场已经在定价其未来的增长？</p>
</div><h2>Preferred P/E of 19.1x: Is it justified?</h2>
<div class="lb-trans"><h2>偏好的市盈率为 19.1 倍：这合理吗？</h2>
</div><p>On a P/E of 19.1x, Grand Pharmaceutical looks slightly cheap versus its own estimated fair P/E, yet more expensive than many Hong Kong pharma peers at the current HK$6.78 share price.</p>
<div class="lb-trans"><p>在 19.1 倍的市盈率下，广药集团相对于其自身估计的合理市盈率显得略微便宜，但在当前 6.78 港元的股价下，相较于许多香港制药同行则显得更贵。</p>
</div><p>The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors pay for each unit of profit. For a diversified pharmaceuticals and medical devices group like Grand Pharmaceutical, this matters because earnings quality, growth forecasts and sector risk can all influence how high or low that multiple settles.</p>
<div class="lb-trans"><p>市盈率将当前股价与每股收益进行比较，是快速了解投资者为每单位利润支付多少的方式。对于像广药集团这样多元化的制药和医疗设备集团来说，这一点很重要，因为盈利质量、增长预测和行业风险都可能影响该倍数的高低。</p>
</div><p>According to the SWS fair ratio work, a P/E closer to 22.5x could be justified. This is higher than the current 19.1x and indicates there could be room for the multiple to move towards that level if earnings forecasts and cash flows develop in line with expectations. At the same time, the shares are trading above the Hong Kong pharmaceuticals industry average P/E of 12x. This indicates the market is already assigning Grand Pharmaceutical a premium versus many local peers based on its earnings profile and outlook.</p>
<div class="lb-trans"><p>根据 SWS 的合理比率研究，接近 22.5 倍的市盈率是合理的。这高于当前的 19.1 倍，并表明如果盈利预测和现金流符合预期，倍数可能有向该水平移动的空间。同时，股票的交易价格高于香港制药行业平均市盈率 12 倍。这表明市场已经根据其盈利状况和前景给予广药集团溢价。</p>
</div><p>Explore the SWS fair ratio for Grand Pharmaceutical Group</p>
<div class="lb-trans"><p>探索广药集团的 SWS 合理比率</p>
</div><p><strong>Result: Price-to-earnings of 19.1x (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：市盈率为 19.1 倍（被低估）</strong></p>
</div><p>However, there are clear risks, including recent share price weakness, a 3 year return of 70.98%, and pressure on profits alongside a reduced dividend.</p>
<div class="lb-trans"><p>然而，存在明显的风险，包括近期股价疲软、三年回报率为 70.98% 以及利润承压和股息减少。</p>
</div><p>Find out about the key risks to this Grand Pharmaceutical Group narrative.</p>
<div class="lb-trans"><p>了解广药集团叙述中的关键风险。</p>
</div><h2>Another view: DCF signals a much bigger gap</h2>
<div class="lb-trans"><h2>另一种观点：DCF 信号显示更大的差距</h2>
</div><p>While the 19.1x P/E suggests Grand Pharmaceutical looks modestly cheap, the SWS DCF model points to a very different picture, with an estimated value of HK$22.44 per share versus the current HK$6.78, implying the shares are heavily undervalued. Which signal do you trust more when the story splits like this?</p>
<div class="lb-trans"><p>虽然 19.1 倍的市盈率表明广药集团看起来略微便宜，但 SWS DCF 模型指向截然不同的图景，估计每股价值为 22.44 港元，而当前股价为 6.78 港元，暗示股票被严重低估。在这种情况下，你更信任哪个信号？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其合理价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTI5" alt="" original-src="https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf?date=2026-03-29"/></p>
<p>512 Discounted Cash Flow as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 512 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Grand Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 237 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看广药集团）。我们展示完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 237 只高质量的被低估股票。如果你保存一个筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>The mixed signals on value, growth and income can feel conflicting, so it makes sense to look through the full set of numbers and form your own view quickly. To weigh the trade off between what could go right and what could go wrong, check the 3 key rewards and 1 important warning sign.</p>
<div class="lb-trans"><p>关于价值、增长和收入的混合信号可能会让人感到矛盾，因此快速查看完整的数字并形成自己的观点是有意义的。要权衡可能的利弊，请查看 3 个关键回报和 1 个重要警告信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Grand Pharmaceutical has sharpened your thinking, do not stop here. Put the same discipline to work across other opportunities while the data is fresh in your mind.</p>
<div class="lb-trans"><p>如果广药集团让你思考更深，不要止步于此。在数据仍然新鲜的情况下，将同样的纪律应用于其他机会。</p>
</div><ul>
<li>Spot potential mispricings by scanning 237 high quality undervalued stocks that pair solid fundamentals with room for the market to catch up.</li>
<li>Strengthen your income stream by reviewing 471 dividend fortresses that focus on higher yields backed by healthier balance sheets.</li>
<li>Dial down portfolio risk by filtering for 270 resilient stocks with low risk scores that score well on resilience and financial stability.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描 237 只高质量的被低估股票，发现潜在的错误定价，这些股票具有稳健的基本面和市场追赶的空间。</li>
<li>通过审查 471 只专注于更高收益且财务状况更健康的股息堡垒，增强你的收入流。</li>
<li>通过筛选 270 只低风险评分且在韧性和财务稳定性方面表现良好的股票，降低投资组合风险。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪你股票的合理价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

A Look At Grand Pharmaceutical Group (SEHK:512) Valuation After 2025 Earnings Reset And New Ophthalmic Drug Approval

Simplywall

香港医药

广发中证香港创新药(QDII-ETF)

博时恒生港股通创新药精选ETF

易方达恒生港股通创新药ETF

华夏医药ETF

华泰柏瑞恒生创新药ETF(QDII)

国泰中证生物医药ETF

汇添富国证港股通创新药ETF

华宝恒生港股通创新药精选ETF

远大医药集团（SEHK:512）在 2025 年收益重置以及新眼科药物获批后的估值分析